专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06225094B1 Method for the genus-specific or/and species-specific detection of bacteria in a sample liquid 失效
标题翻译：用于样品液体中细菌的特异性或/和物种特异性检测的方法
公开(公告)号：US06225094B1
公开(公告)日：2001-05-01
申请号：US08073985
申请日：1993-06-08
申请人： Wolfgang Ludwig , Karl-Heinz Schleifer , Christoph Kessler , Ruediger Rueger , Anne Stern
发明人： Wolfgang Ludwig , Karl-Heinz Schleifer , Christoph Kessler , Ruediger Rueger , Anne Stern
IPC分类号： C12P1934
CPC分类号： C12Q1/689 , C12Q1/6858
摘要： For the genus-specific or/and species-specific detection of bacteria in a sample liquid, bacterial RNA is hybridized with a primer which is complementary to a genus-specific or species-specific region of the RNA of particular bacteria or to a highly conserved region of the RNA of bacteria in general, but which is not complementary at its 3′ end to the RNA of bacteria of another genus or species, the primer is elongated in the presence of a suitable polymerase and the four deoxyribonucleotides, if desired, with a concurrent or subsequent labelling of the elongation product and an elongation product formed is hybridized with a genus-specific or species-specific oligonucleotide after denaturation and the hybridization is detected by means of the oligonucleotide label.
摘要翻译：对于样品液体中细菌的特异性或/和物种特异性检测，细菌RNA与与特定细菌的RNA的特异性或物种特异性区域互补的引物杂交，或与高度保守的一般细菌的RNA的区域，但是在其3'末端与另一属或物种的细菌的RNA不互补，则引物在合适的聚合酶存在下延长，如果需要，四种脱氧核糖核苷酸与延伸产物的同时或随后的标记和形成的延伸产物与变性后的属特异性或物种特异性寡核苷酸杂交，并通过寡核苷酸标记检测杂交。

2. 发明申请

US20100249379A1 PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS 有权
标题翻译：来自多种核酸的蛋白质表达
公开(公告)号：US20100249379A1
公开(公告)日：2010-09-30
申请号：US12681781
申请日：2008-10-09
申请人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
发明人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
IPC分类号： C07K16/28 , C12P21/08
CPC分类号： C12N15/85 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K2317/14 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C12P21/00
摘要： The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium.
摘要翻译：本发明报告了在CHO细胞中重组产生分泌的异源免疫球蛋白的方法，其包括以下步骤：i）提供适于在悬浮培养物中生长的CHO细胞，适于在无血清培养基中生长，支原体免费和无病毒，ii）提供包含原核复制起点的载体，赋予原核选择剂抗性的第一核酸，编码所述异源免疫球蛋白的重链的第二核酸，编码光的第三核酸所述异源免疫球蛋白链，赋予对真核选择剂的抗性的第四核酸，iii）转染所述CHO细胞，其中所述转染包括a）用包含第四核酸的所述载体转染所述CHO细胞，所述第四核酸赋予对第一真核选择性的抗性试剂，b）通过在含有所述第一种真核生物的培养基中生长来选择CHO细胞 c）用所述载体转染所述选择的CHO细胞，所述载体包含赋予与所述第一真核选择试剂不同的第二真核选择剂的抗性的第四核酸，d）通过在含有所述第一和第二真核选择试剂的培养基中选择生长来选择CHO细胞，所述第二真核选择剂，iv）在所述第一和第二真核选择剂的存在下，在适于表达所述第二和第三核酸的条件下，在培养基中培养所述转染的CHO细胞，和v）回收所述分泌的异源免疫球蛋白。

3. 发明授权

US07563441B2 Anti-P-selectin antibodies 有权
标题翻译：抗P-选择素抗体
公开(公告)号：US07563441B2
公开(公告)日：2009-07-21
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译：本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。

4. 发明授权

US07008764B1 Optimization of cells for endogenous gene activation 有权
标题翻译：内源基因激活的细胞优化
公开(公告)号：US07008764B1
公开(公告)日：2006-03-07
申请号：US09203500
申请日：1998-12-01
申请人： Konrad Honold , Thomas Holtschke , Anne Stern
发明人： Konrad Honold , Thomas Holtschke , Anne Stern
IPC分类号： C12Q1/68
CPC分类号： C07K14/505 , C12N15/63 , C12N15/65 , C12N15/85 , C12N15/90 , C12N15/907 , C12N2800/30 , C12N2830/002 , C12Q1/6897
摘要： The invention concerns a process for optimizing the gene expression in cells. A first aspect concerns a process for changing the expression of a nucleic acid sequence which is present endogenously in a eukaryotic cell by introduction of a heterologous expression control sequence into the genome of the cell by means of homologous recombination as well as site-specific recombinase-mediated excision of inserted foreign DNA and its replacement by further heterologous expression control sequences or/and amplification genes. In addition the invention concerns the introduction of one or several nucleic acid sequences to which an activator protein or an activator protein complex binds e.g. a hypoxia-inducible factor (HIF), into the genome of a eukaryotic cell by homologous recombination in order to change the expression of a target gene. Furthermore the invention concerns a process for testing the influence of 5′ or 3′ non-coding nucleic acid fragments on the expression of a target gene by determining the expression of a reporter gene. In addition the invention concerns a process for providing a DHFR-negative eukaryotic cell containing a recombinase target sequence as well as the expression of a nucleic acid sequence inserted into the recombinase target sequence.
摘要翻译：本发明涉及优化细胞中基因表达的方法。第一方面涉及一种通过将异源表达控制序列通过同源重组以及位点特异性重组酶导入到细胞基因组中而在真核细胞中内源性存在的核酸序列的表达的方法。介导的插入的外源DNA的切除及其通过进一步的异源表达控制序列或/和扩增基因的替代。此外，本发明涉及一种或几种核酸序列的引入，活化蛋白或活化蛋白复合物例如与其结合。缺氧诱导因子（HIF），通过同源重组进入真核细胞的基因组，以改变靶基因的表达。此外，本发明涉及通过测定报告基因的表达来测试5'或3'非编码核酸片段对靶基因表达的影响的方法。此外，本发明涉及提供含有重组酶靶序列的DHFR阴性真核细胞以及插入重组酶靶序列中的核酸序列的表达的方法。

5. 发明授权

US5223422A t-PA mutant GK1L 失效
标题翻译： T-PA MUTANT GK1L
公开(公告)号：US5223422A
公开(公告)日：1993-06-29
申请号：US671776
申请日：1991-04-16
申请人： Ulrich Weidle , Anne Stern
发明人： Ulrich Weidle , Anne Stern
IPC分类号： C12N15/09 , A61K38/00 , A61K38/46 , A61P7/02 , C07K14/00 , C12N1/15 , C12N5/10 , C12N9/64 , C12N9/72 , C12N15/58 , C12R1/91
CPC分类号： C12N9/6459 , C12Y304/21069 , A61K38/00
摘要： The invention concerns a recombinant DNA which codes for a protein with the domains G, K1 and L of t-PA in which the sequences coding for the domains K2 and F of the wild-type t-PA gene or the sequences derived therefrom within the scope of the degeneration of the genetic code are completely deleted according to the exact exon/intron borders on the t-PA gene. The invention also relates to a process for the production of a recombinant DNA according to the present invention. In addition the invention concerns vectors containing this recombinant DNA as well as cells which are transformed with vectors according to the present invention or with the DNA according to the present invention. Furthermore the invention provides a protein with fibrinolytic properties by expression of a DNA sequence according to the present invention in suitable host cells which consists of the amino acid sequences of the domains G, K1 and L of t-PA in this order and which, if desired, is glycosylated as well as a process for its production. Finally the invention also concerns a fibrinolytic agent containing a protein according to the present invention.
摘要翻译： PCT No.PCT / EP90 / 01401 Sec。 371日期1991年5月24日 102（e）日期1991年5月24日PCT提交1990年8月22日PCT公布。出版物WO91 / 02798 1991年3月7日。本发明涉及编码具有t-PA结构域G，K1和L的蛋白质的重组DNA，其中编码野生型t-PA基因的结构域K2和F的序列或者在遗传密码子的退化范围内衍生自其的序列根据t-PA基因上的确切的外显子/内含子边界被完全删除。本发明还涉及根据本发明的重组DNA的制备方法。此外，本发明涉及含有该重组DNA的载体以及根据本发明的载体或根据本发明的DNA转化的细胞。此外，本发明提供了一种具有纤维蛋白溶解性质的蛋白质，其通过根据本发明的DNA序列在合适的宿主细胞中表达，所述合适的宿主细胞由t-PA的结构域G，K1和L的氨基酸序列依次组成，所需的是糖基化的，以及其生产方法。最后，本发明还涉及含有根据本发明的蛋白质的纤维蛋白溶解剂。

6. 发明授权

US08771988B2 Protein expression from multiple nucleic acids 有权
标题翻译：来自多个核酸的蛋白质表达
公开(公告)号：US08771988B2
公开(公告)日：2014-07-08
申请号：US12681781
申请日：2008-10-09
申请人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
发明人： Ulrich Goepfert , Hendrik Knoetgen , Erhard Kopetzki , Anne Stern
IPC分类号： C12P21/08
CPC分类号： C12N15/85 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K2317/14 , C07K2317/21 , C07K2317/51 , C07K2317/515 , C12P21/00
摘要： The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfecting said selected CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a second eukaryotic selection agent different to said first eukaryotic selection agent, d) selecting a CHO cell by selected growth in cultivation medium containing said first and said second eukaryotic selection agent, iv) cultivating said transfected CHO cell in a medium in the presence of said first and second eukaryotic selection agent, under conditions suitable for the expression of said second, and third nucleic acid, and v) recovering said secreted heterologous immunoglobulin from the cultivation medium.
摘要翻译：本发明报告了在CHO细胞中重组产生分泌的异源免疫球蛋白的方法，其包括以下步骤：i）提供适于在悬浮培养物中生长的CHO细胞，适于在无血清培养基中生长，支原体免费和无病毒，ii）提供包含原核复制起点的载体，赋予原核选择剂抗性的第一核酸，编码所述异源免疫球蛋白的重链的第二核酸，编码光的第三核酸所述异源免疫球蛋白链，赋予对真核选择剂的抗性的第四核酸，iii）转染所述CHO细胞，其中所述转染包括a）用包含第四核酸的所述载体转染所述CHO细胞，所述第四核酸赋予对第一真核选择性的抗性试剂，b）通过在含有所述第一种真核生物的培养基中生长来选择CHO细胞 c）用所述载体转染所述选择的CHO细胞，所述载体包含赋予与所述第一真核选择剂不同的第二真核选择剂的抗性的第四核酸，d）通过在含有所述第一和第二真核选择剂的培养基中选择生长来选择CHO细胞，所述第二真核选择剂，iv）在所述第一和第二真核选择剂的存在下，在适于表达所述第二和第三核酸的条件下，在培养基中培养所述转染的CHO细胞，和v）回收所述分泌的异源免疫球蛋白。

7. 发明申请

US20050226876A1 Anti-P-selectin antibodies 有权
标题翻译：抗P-选择素抗体
公开(公告)号：US20050226876A1
公开(公告)日：2005-10-13
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28 , C07K16/46 , C07H21/04 , C12N5/06 , C12N15/09
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译：本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。

8. 发明授权

US06555373B1 Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof 有权
标题翻译：用于鉴定用于内源基因激活的人细胞系分离鉴定的人细胞系的方法及其用途
公开(公告)号：US06555373B1
公开(公告)日：2003-04-29
申请号：US09607277
申请日：2000-06-30
申请人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll , Reinhard Franze , Ulrich Pessara
发明人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll , Reinhard Franze , Ulrich Pessara
IPC分类号： C12N502
CPC分类号： C07K14/505 , A61K38/00 , C07K2319/02 , C07K2319/036 , C07K2319/75 , C12N15/10 , C12N15/625 , C12P21/005
摘要： The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.
摘要翻译：本发明涉及由于内源性人EPO基因的活化能够产生足够数量和纯度的EPO以使作为药物制剂的人EPO成本有效的生产的人细胞。此外，本发明涉及生产这种人EPO产生细胞的方法，用于激活人细胞内源性EPO基因的DNA构建体以及在人细胞中大规模生产EPO的方法。

9. 发明授权

US06544748B2 Preparation of erythropoietin by endogenous gene activation 有权
公开(公告)号：US06544748B2
公开(公告)日：2003-04-08
申请号：US09985357
申请日：2001-11-02
申请人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll
发明人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll
IPC分类号： C12Q168
CPC分类号： C07K14/505 , A61K38/00 , C07K2319/02 , C07K2319/036 , C07K2319/75 , C12N15/10 , C12N15/625 , C12P21/005
摘要： The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.

10. 发明授权

US06391633B1 Production of erythropoietin by endogenous gene activation 有权
标题翻译：通过内源基因激活产生促红细胞生成素
公开(公告)号：US06391633B1
公开(公告)日：2002-05-21
申请号：US09463380
申请日：2000-01-21
申请人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll
发明人： Anne Stern , Michael Brandt , Konrad Honold , Johannes Auer , Hans Koll
IPC分类号： C12N506
CPC分类号： C07K14/505 , A61K38/00 , C07K2319/02 , C07K2319/036 , C07K2319/75 , C12N15/10 , C12N15/625 , C12P21/005
摘要： The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO inhuman cells, and a method for the large technical production of EPO in human cells.
摘要翻译：本发明涉及能够以内源性人EPO基因的活化为基础的以足够量和纯度生产EPO的人细胞，从而使作为药物制剂的人EPO成本有效地生产成为可能。本发明还涉及制备这种人EPO产生细胞的方法，用于激活内源性EPO非人细胞的DNA构建体，以及人细胞中大量技术生产EPO的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式